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Diclofenac is one of the most widely prescribed non-steroidal anti-inflammatory
drugs (NSAIDs). Use of diclofenac is associated with two major limitations; first, rare,
but serious and sometimes fatal, gastrointestinal (GI) side-effects, including ulceration,
and hemorrhage, especially in the elderly (1, 2), and second, poor water solubility.
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Pharmacosomes are amphiphilic lipid vesicular systems
that have shown their potential in improving the bio-
availability of poorly water soluble as well as poorly li-
pophilic drugs. Diclofenac is a poorly water soluble drug
and also causes gastrointestinal toxicity. To improve the
water solublity of diclofenac, its pharmacosomes (pho-
spholipid complex) have been prepared and evaluated
for physicochemical analysis. Diclofenac was complexed
with phosphatidylcholine (80 %) in equimolar ratio, in
the presence of dichloromethane, by the conventional sol-
vent evaporation technique. Pharmacosomes thus prepa-
red were evaluated for drug solubility, drug content, sur-
face morphology (by scanning electron microscopy), phase
transition behaviour (by differential scanning calorime-
try), crystallinity (by X-ray powder diffraction) and in vitro
dissolution. Pharmacosomes of diclofenac were found to
be irregular or disc shaped with rough surfaces in SEM.
Drug content was found to be 96.2 ± 1.1 %. DSC thermo-
grams and XRPD data confirmed the formation of the
phospholipid complex. Water solubility of the prepared
complex was found to be 22.1 mg mL–1 as compared to
10.5 mg mL–1 of diclofenac. This improvement in water
solubility in prepared pharmacosomes may result in im-
proved dissolution and lower gastrointestinal toxicity.
Pharmacosomes showed 87.8 % while the free diclofenac
acid showed a total of only 60.4 % drug release at the end
of 10 h of dissolution study.
Keywords: diclofenac, solubility, pharmacosomes, phospho-
lipid complex
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Different approaches have been applied to decrease NSAID-induced GI toxicity. For
example, association of NSAIDs with phospholipids has been suggested to improve GI
safety of these drugs (3). The presence of an adsorbed layer of surface-active phospho-
lipids on the surface of the mucus that covers the surface epithelium is suggested to pro-
tect the GI tissues by providing a hydrophobic layer between the epithelium and the lu-
minal contents (4, 5). It has been reported that NSAIDs associated with zwitterionic
phospholipids may reduce GI toxicity (3).
Besides GI toxicity of diclofenac, it is also poorly water soluble, due to which its dis-
solution in GI fluid is very low, which in turn adversely affects the bioavailability (50–60
% only). The association of diclofenac with zwitterionic phospholipids, which may be
both electrostatic and hydrophobic in nature, renders the phospholipids more water-sol-
uble and the NSAID more lipid-soluble (6). It has been reported that the diffusion of
NSAIDs across lipid membranes and into target cells is accelerated when they are in a
complex with phosphatidylcholine (PC) (3).
Therefore developing drugs as lipid complexes (pharmacosomes) may be a poten-
tial approach to improve solubility and to minimize the GI toxicity of diclofenac. Phar-
macosomes are amphiphilic drug-lipid complexes, which are stable and more bioavai-
lable drug delivery systems with low interfacial tension between the system and the GI
fluid, thereby facilitating the membrane, tissue, or cell wall transfer in the organism (7).
This work aims to develop and characterize the pharmacosomes of diclofenac along
with its in vitro drug release study.
EXPERIMENTAL
Materials
Diclofenac potassium was obtained as a gift sample from Wings Pharma, India.
Soya phosphatidylcholine (LIPOID S-80) was obtained as a gift sample from LIPOID, Ger-
many. All other chemicals were of analytical grade.
Formulation of pharmacosomes
Diclofenac salt was converted into the acid form to provide an active hydrogen site
for complexation. Diclofenac acid was prepared by acidification of an aqueous solution
of diclofenac potassium, extraction into chloroform, and subsequent recrystallization.
Diclofenac-PC complex was prepared by associating diclofenac acid with an equimolar
concentration of PC. The equimolar concentration of PC and diclofenac acid were placed
in a 100-mL round bottom flask and dissolved in dichloromethane. The solvent was eva-
porated under vacuum at 40 °C in a rotary vacuum evaporator (Perfit Model No. 5600,
Büchi type, Perfit Ltd., India). The pharmacosomes were collected as the dried residue
and placed in a vacuum desiccator overnight and then subjected to characterization.
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Drug content
To determine the drug content in pharmacosomes of diclofenac (diclofenac-PC com-
plex), a complex equivalent to 50 mg diclofenac was weighed and added into a volumet-
ric flask with 100 mL of pH 6.8 phosphate buffer. Then the volumetric flask was stirred
continuously for 24 h on a magnetic stirrer. At the end of 24 h, suitable dilutions were
made and measured for the drug content at 276 nm UV spectrophotometrically (double
beam UV-Visible spectrophotometer, Lambda 25, Perkin Elmer, USA).
Solubility
To determine the change in solubility due to complexation, solubility of diclofenac
acid and diclofenac-PC complex was determined in pH 6.8 phosphate buffer and n-oc-
tanol by the shake-flask method. Diclofenac acid (50 mg) (and 50 mg equivalent in case
of complex) was placed in a 100-mL conical flask. Phosphate buffer pH 6.8 (50 mL) was
added and then stirred for 15 minutes. The suspension was then transferred to a 250 mL
separating funnel with 50 mL n-octanol and was shaken well for 30 minutes. Then the
separating funnel was kept still for about 30 minutes. Concentration of the drug was de-
termined from the aqueous layer spectrophotometrically at 276 nm.
Scanning electron microscopy (SEM)
To detect the surface morphology of the pharmacosomes, SEM of the complex was
recorded on a scanning electron microscope (JEOL JSM 5600, Japan).
Differential scanning calorimetry (DSC)
Thermograms of diclofenac acid, phosphatidylcholine (80 %) and the diclofenac-
-PC complex were recorded using a 2910 Modulated Differential Scanning Calorimeter
V4.4E (TA Instruments, USA). The thermal behavior was studied by heating 2.0 ± 0.2 mg
of each individual sample in a covered sample pan under nitrogen gas flow. The in-
vestigations were carried out over the temperature range 25–250 °C at a heating rate
of 10 °C min–1.
X-ray powder diffraction (XRPD)
The crystalline state of diclofenac in the different samples was evaluated using
X-ray powder diffraction. Diffraction patterns were obtained on a Bruker Axs- D8 Dis-
cover Powder X-ray diffractometer, Germany. The X-ray generator was operated at 40
kV tube voltages and 40 mA tube current, using the K a lines of copper as the radiation
source. The scanning angle ranged from 1 to 60° of 2q in the step scan mode (step width
0.4° min–1). Diclofenac acid, phosphatidylcholine 80 % (Lipoid S-80) and the prepared
complex were analyzed. The results are shown in Fig. 3.
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Dissolution study
In vitro dissolution studies of diclofenac complex as well as plain diclofenac acid
were performed in triplicate in a USP (8) six station dissolution test apparatus, type II
(Veego Model No. 6 DR, India) at 100 rpm and at 37 °C. An accurately weighed amount
of the complex equivalent to 100 mg of diclofenac acid was put into 900 mL of pH 6.8
phosphate buffer. Samples (3 mL each) of dissolution fluid were withdrawn at different
intervals and replaced with an equal volume of fresh medium to maintain sink condi-
tions. Withdrawn samples were filtered (through a 0.45-mm membrane filter), diluted
suitably and then analyzed spectrophotometrically at 276 nm. Fig. 4 gives a graphical
representation of the in vitro release profile from the formulations.
Statistical analysis
Results are expressed as mean values ± standard deviations and the significance of
the difference observed was analyzed by Student’s t-test.
RESULTS AND DISCUSSION
Pharmacosomes of diclofenac were prepared with an equimolar ratio (1:1) of diclo-
fenac and phopsphatidylcholine in the presence of dichloromethane by the conventional
solvent evaporation technique. The content of diclofenac in the pharmacosome, as esti-
mated by UV spectrophotometry, was found to be 96.2 ± 1.1 % (m/m). Pharmacosomes
showed a high percentage of drug loading, which is specific to them. Complexation pro-
vides good percent loading of the drug, which makes the drug delivery clinically feasi-
ble. On the other hand, in liposomes of diclofenac sodium, the encapsulation efficiency
was found to be just 59 % (9). Special methods such as coating of these vesicular systems
were needed to improve the loading of the drug. This is not required in the pharmaco-
somes in which the drug is reversibly bonded chemically with the lipids and thus shows
not only good percent loading but also better stability than in liposomes.
Water solubility of diclofenac from pharmacosomes was found to be much higher
than that of diclofenac acid. Table I provides the solubility data. The increase in solubi-
lity of diclofenac acid in the complex can be explained by the fact that solubilization re-
sulted from the micelle formation in the medium and by the amorphous characteristics
of the complex. As amphiphilic surfactants, phospholipids could increase the solubility
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Table I. Solubility study of diclofenac acid and its pharmacosomes
Drug
Solubility
Aqueous layer (mg mL–1)a n-Octanol layer (mg mL–1) a
Diclofenac acid 10.5 ± 1.5 30.5 ± 1.0
Diclofenac pharmacosomes 22.1 ± 2.4 32.5 ± 1.4
a Mean ± SD; n = 3.
of the drug by the action of wetting and dispersion (3, 6). Unlike the non-polar nature of
diclofenac, the complex showed amphiphilic nature, which may prove to be responsible
for improved bioavailability of the drug (10).
Scanning electron micrographs of the complex are shown in Fig. 1. Pharmacosomes
were found to be irregular or disc shaped with rough surface morphology. The complex
was found to involve free flowing particles. Phospholipids are natural components, so
their different purity grades may have different effects on the shape and surface mor-
phology (11).
In order to substantiate the association of diclofenac acid with PC, DSC analysis was
performed on diclofenac acid, PC, and the pharmacosomes of diclofenac. Results con-
firmed the association of diclofenac acid and PC in the complex as both peaks represent-
ing diclofenac acid and PC changed positions. Phospholipids (Fig. 2b) showed two ma-
jor peaks at 83.21 °C and 107.90 °C and a small peak at 64.45 °C. The first peak of pho-
spholipids is a mild peak (at 64.45 °C), which is probably due to the hot movement of
the phospholipid polar head group. The second (83.21 °C) peak is very sharp, which ap-
pears to be due to the phase transition from gel to liquid crystalline state. The non-polar
hydrocarbon tail of phospholipids may be melted during this phase, yielding a sharp
peak. This melting might have occurred in two phases that subsequently gave another
peak (107.90 °C), which is relatively less sharp. Diclofenac acid (Fig. 2a) showed a sharp
endothermic peak at 171.31 °C. On the other hand, pharmacosomes of diclofenac (Fig.
2c) showed a broad peak at 68.34 °C, which is different from the peaks of the individual
components of the complex. It is evident that the original peaks of diclofenac and pho-
spholipids disappear from the thermogram of pharmacosomes (complex) and the phase
transition temperature is lower than that of phospholipids. The DSC thermograms of the
phospholipid complexes of some phytoconstituents, like silybin, puerarin, curcumin and
some xanthones, revealed similar results (12–14).
To check whether the changes in the diclofenac crystal morphology correspond to a
polymorphic transition and to study the solid state of diclofenac phospholipid complex,
XRPD analysis was conducted. The XRPD of diclofenac complex revealed a broad peak
similar to PC (Fig. 3). It suggested that the diclofenac in the phospholipid complex was
either in amorphous form or molecularly dispersed. These results are well supported by
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a) b)
Fig. 1. SEM of pharmacosomes of diclofenac: a) 190X magnification, b) 950X magnification.
our previous studies done with the phospholipid complexes of aspirin (11). The disap-
pearance of diclofenac crystalline diffraction peaks confirmed the formation of the pho-
spholipid complex. Unlike liposomes, chemical bonding between the drug and phospho-
lipids in the development of pharmacosomes might have resulted into a significant change
of its X-ray diffraction.
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Fig. 2. DSC thermograms of: a) diclofenac acid, b) phosphatidylcholine, and c) pharmacosome of
diclofenac.
The pharmacosomes of diclofenac showed a better dissolution profile than diclofe-
nac acid (Fig. 4). Unlike free diclofenac acid (which showed only 60.4 % drug release at
the end of 10 h) the diclofenac complex showed 87.8 % at the end of 10 h of the dissolu-
tion study in pH 6.8 phosphate buffer. Solid dissolution is a complex operation influ-
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Fig. 4. Dissolution study of pharmacosomes of diclofenac and diclofenac acid (mean ± SD; n = 3).
enced by a number of factors, not only by particle size. Differences in the crystal habit,
surface area, surface energies, particle size and wettability may all play a role in affect-
ing the dissolution rate of powder (15). Phospholipids being amphiphilic surfactants, in-
creased the solubility of the drug by the action of wetting and dispersion. That is why
the dissolution profile of the complex was found to be improved. In some studies done
with silybin and xanthones, the in vitro drug release from the complexes was found to be
pH dependent and with the increase of the medium pH the drug dissolution was in-
creased (12).
CONCLUSIONS
In the present study, a diclofenac-phospholipid complex (pharmacosomes) was pre-
pared by a simple and reproducible method and evaluated for various physicochemical
parameters. Physicochemical investigations showed that diclofenac formed a stoichio-
metric complex with phospholipid with improved solubility and dissolution profile. DSC
and XRPD studies confirmed the formation of the complex. Thus it can be concluded
that the pharmacosomes of diclofenac may be of potential use for improving dissolution
and for reducing the gastrointestinal toxicity of the drug.
Pharmacosomes may be developed also for other NSAIDs with poor bioavailability
and GI side effects. Moreover, the pharmacosomes of phytoconstituents (with poor wa-
ter and/or lipid solubility) may also be developed for improving their aqueous solubi-
lity and lipophilicity and hence bioavailability.
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S A _0length E T A K
Razvoj i fizikokemijsko vrednovanje farmakosoma diklofenaka
AJAY SEMALTY, MONA SEMALTY, DEVENDRA SINGH i M. S. M. RAWAT
Farmakosomi su amfifilni lipidni vezikularni sustavi sa sposobno{}u pobolj{anja
bioraspolo`ivosti lijekova slabo topljivih u vodi i organskim otapalima. U svrhu pove}a-
nja topljivosti diklofenaka (ljekovite tvari koja je slabo vodotopljiva, a uzrokuje i gastro-
intestinalnu toksi~nost) pripravljeni su i evaluirani njegovi farmakosomi (fosfolipidni
kompleksi). Diklofenak je kompleksiran s fosfatidilkolinom (80 %) u ekvimolarnom omje-
ru, u prisutnosti diklormetana, konvencionalnom metodom evaporacije. Tako priprav-
ljenim farmakosomima ispitivana je topljivost, sadr`aj ljekovite tvari, morfologija povr-
{ine (pomo}u pretra`ne elektronske mikroskopije), pona{anje pri prijelazu faza (pomo}u
diferencijalne pretra`ne kalorimetrije), kristalini~nost (rendgenskom analizom praha) i in
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vitro osloba|anje. Farmakosomi diklofenaka su nepravilnog oblika ili u obliku diska te
imaju neravnu povr{inu u SEM-u. Sadr`aj ljekovite tvari je 96,2 ± 1,1 %. DSC termogra-
mi i XRPD podaci potvrdili su nastajanje fosfolipidnog kompleksa. Topljivost u vodi do-
bivenih kompleksa bila je 22,1 mg mL–1, a topljivost samog diklofenaka 10,5 mg mL–1.
Postignuto pobolj{anje topljivosti mo`e imati za posljedicu pove}ano osloba|anje i ma-
nju gastrointestinalnu toksi~nost. Tijekom 10 h iz farmakosoma se oslobodilo 87,8 %, a iz
slobodnog diklofenaka samo 60,4 % ljekovite tvari.
Klju~ne rije~i: diklofenak, topljivost, farmakosomi, fosfolipid kompleks
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